Kite Pharma

Kite publishes Phase II data for Yescarta in treating B-cell lymphoma
Kite publishes Phase II data for Yescarta in treating B-cell lymphoma
Clinical Trials Arena
Gilead Sciences
Kite Pharma
Yescarta
clinical trials
CAR-T
relapsed or refractory large B-cell lymphoma
Flag link:
Kite's Yescarta CAR T-cell Therapy Shows Extended Survival in Relapsed/Refractory Large B-cell Lymphoma
Kite's Yescarta CAR T-cell Therapy Shows Extended Survival in Relapsed/Refractory Large B-cell Lymphoma
Businesswire
ASCO 2023
Gilead Sciences
Kite Pharma
Yescarta
relapsed or refractory large B-cell lymphoma
Flag link:
Gilead picks former Roche executive to run cell therapy unit Kite
Gilead picks former Roche executive to run cell therapy unit Kite
BioPharma Dive
Gilead Sciences
Roche
Kite Pharma
cell therapy
Cindy Perettie
women executives
Flag link:
After years of back-and-forth, Gilead's CAR-T Yescarta sways England's cost watchdog NICE
After years of back-and-forth, Gilead's CAR-T Yescarta sways England's cost watchdog NICE
Fierce Pharma
Gilead Sciences
CAR-T
Yescarta
UK
NICE
Kite Pharma
Novartis
blood cancer
Flag link:
Kite swoops in to buy Carl June-founded Tmunity, gaining key to Penn's CAR-T research apparatus
Kite swoops in to buy Carl June-founded Tmunity, gaining key to Penn's CAR-T research apparatus
Fierce Biotech
Kite Pharma
Gilead Sciences
M&A
CAR-T
Tmunity
Carl June
Flag link:
Gilead lands new cell therapy for Kite in $225M Arcellx deal
Gilead lands new cell therapy for Kite in $225M Arcellx deal
Fierce Biotech
Gilead Sciences
Kite Pharma
Arcellx
clinical trials
Multiple Myeloma
cell therapy
JNJ
Legend Biotech
Flag link:
Gilead dodges Supreme Court review—and a $1.2B fine—in CAR-T patent feud with Bristol Myers
Gilead dodges Supreme Court review—and a $1.2B fine—in CAR-T patent feud with Bristol Myers
Fierce Pharma
Gilead Sciences
Kite Pharma
Bristol Myers Squibb
cell therapy
legal
CAR-T
Yescarta
Flag link:
FDA Review: Alnylam, Cytokinetics, Eli Lilly and More
FDA Review: Alnylam, Cytokinetics, Eli Lilly and More
BioSpace
FDA
Alnylam
Cytokinetics
Eli Lilly
Owlet
Boston Cell Standards
Kiromic Biopharma
Entera Bio
Transcenta Holdings
Kira Pharmaceuticals
Kite Pharma
Poxel
Seneca Therapeutics
Flag link:
Gilead hits back at Bristol Myers' Supreme Court petition in CAR-T patent feud
Gilead hits back at Bristol Myers' Supreme Court petition in CAR-T patent feud
Fierce Pharma
Gilead Sciences
CAR-T
patents
Supreme Court
Kite Pharma
Bristol Myers Squibb
Flag link:
Kite’s Maryland CAR T-cell therapy site gets FDA go-ahead
Kite’s Maryland CAR T-cell therapy site gets FDA go-ahead
Biopharma Reporter
Kite Pharma
Gilead Sciences
FDA
CAR-T
drug manufacturing
Yescarta
Flag link:
Gilead beats BMS to FDA okay for early lymphoma CAR-T therapy
Gilead beats BMS to FDA okay for early lymphoma CAR-T therapy
Pharmaforum
Gilead Sciences
Kite Pharma
CAR-T
Bristol Myers Squibb
lymphoma
large B-cell lymphoma
Flag link:
Kite gets US FDA approval for Tecartus to treat acute lymphoblastic leukemia
Kite gets US FDA approval for Tecartus to treat acute lymphoblastic leukemia
Pharmaceutical Business Review
Kite Pharma
Gilead Sciences
Tecartus
FDA
ALL
acute lymphoblastic leukemia
Flag link:
Gilead wins reversal of $1.2B fine in CAR-T patent fight with Bristol Myers
Gilead wins reversal of $1.2B fine in CAR-T patent fight with Bristol Myers
Fierce Pharma
Gilead Sciences
Kite Pharma
CAR-T
patents
Bristol Myers Squibb
Flag link:
Gilead's Kite, Appia Bio to Collaborate on Allogeneic Cell Therapies for Cancer
Gilead's Kite, Appia Bio to Collaborate on Allogeneic Cell Therapies for Cancer
Marketwatch
Gilead Sciences
Kite Pharma
Appia Bio
cancer
cell therapy
Flag link:
BioNTech returns to cancer roots with deal for Gilead cell therapy factory
BioNTech returns to cancer roots with deal for Gilead cell therapy factory
BioPharma Dive
BioNTech
cancer
Gilead Sciences
Kite Pharma
cell therapy
Flag link:
Gilead's Kite earns second-line win for CAR-T Yescarta, setting up a battle over earlier blood cancer patients
Gilead's Kite earns second-line win for CAR-T Yescarta, setting up a battle over earlier blood cancer patients
Endpoints
Gilead Sciences
Kite Pharma
Yescarta
relapsed or refractory diffuse large B-cell lymphoma
CAR-T
Flag link:
#ASCO21: A week after nabbing priority review, Kite unveils the pivotal data it hopes will lead to a new CAR-T approval
#ASCO21: A week after nabbing priority review, Kite unveils the pivotal data it hopes will lead to a new CAR-T approval
Endpoints
ASCO 2021
Kite Pharma
Gilead Sciences
CAR-T
Tecartus
Flag link:
Kite: New data offers transparency into CAR T cell therapy manufacturing in real world setting
Kite: New data offers transparency into CAR T cell therapy manufacturing in real world setting
Biopharma Reporter
Kite Pharma
Yescarta
CAR-T
Flag link:
'Can't say no': Kite Pharma taps Frank Neumann as new head of clinical development
'Can't say no': Kite Pharma taps Frank Neumann as new head of clinical development
Endpoints
Kite Pharma
Gilead Sciences
clinical development
Flag link:
After bagging Yescarta exec as CMO, T-cell biotech NexImmune files for $86M IPO
After bagging Yescarta exec as CMO, T-cell biotech NexImmune files for $86M IPO
Fierce Biotech
NexImmune
Gilead Sciences
Kite Pharma
IPOs
Flag link:

Pages